Author | Ari VanderWalde, MD | OncLive

Author | Ari VanderWalde, MD


Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021

March 23, 2018

Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.